Imara Inc IMRA:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/01/21 EST
13.86quote price arrow up+1.27 (+10.09%)
Volume
147,151
52 week range
11.85 - 62.71

...

Loading . . .

KEY STATS

  • Open12.80
  • Day High13.98
  • Day Low12.73
  • Prev Close13.86
  • 52 Week High62.71
  • 52 Week High Date06/09/20
  • 52 Week Low11.85
  • 52 Week Low Date02/23/21
  • Market Cap241.30M
  • Shares Out17.41M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-5.98
  • P/E (TTM)-2.32
  • Fwd P/E (NTM)-3.39
  • EBITDA (MRQ)-31.97M
  • ROE (MRQ)-110.78%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Imara Inc News

There is no recent news for this security.

Latest IMRA News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Imara, Inc. is a clinical-stage biopharmaceutical company. The Company is developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. The Company’s product pipeline include IMR-687, which is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease (SCD), and beta-thalassemia. Its IMR-687 is a selective, small molecule inhibitor of phosphodiesterase-9 (PDE9). The Company is conducting...
David Mott
Chairman
Rahul Ballal Ph.D.
President
Michael Gray
Chief Financial Officer
Address
116 HUNTINGTON AVENUE, 6TH FLOOR
Boston, MA
02116
United States